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Objective: The role of inﬂammation in osteoarthritis (OA) pathogenesis is unclear, and the associations
between inﬂammatory cytokines and cartilage loss have not been reported. We determined the asso-
ciations between serum levels of interleukin (IL)-6 and tumor necrosis factor-a (TNF-a), knee radio-
graphic OA (ROA) and cartilage loss over 2.9 years in older adults.
Methods: A total of 172 randomly selected subjects (mean 63 years, range 52e78, 47% female) were
studied at baseline and approximately 3 (range 2.6e3.3) years later. IL-6 and TNF-a were assessed by
radioimmunoassay. T1-weighted fat-suppressed magnetic resonance imaging of the right knee was
performed at baseline and follow-up to determine knee cartilage volume. Knee ROA of both knees was
assessed at baseline.
Results: At baseline, quartiles of IL-6 and TNF-a were associated with increased prevalence of medial
tibiofemoral joint space narrowing (OARSI grade 1) in multivariate analyses [odds ratio (OR): 1.42 and
1.47 per quartile, respectively, both P< 0.05]. Longitudinally, baseline IL-6 predicted loss of both medial
and lateral tibial cartilage volume (b: 1.19% and 1.35% per annum per quartile, P< 0.05 and P< 0.01,
respectively), independently of TNF-a. Change in IL-6 was associated with increased loss of medial and
lateral tibial cartilage volume (b: 1.18% and 1.06% per annum per quartile, both P< 0.05) and change
in TNF-a was also negatively associated with change in medial cartilage volume (b: 1.27% per annum
per quartile, P< 0.05).
Conclusions: Serum levels of IL-6 and TNF-a are associated with knee cartilage loss in older people
suggesting low level inﬂammation plays a role in the pathogenesis of knee OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is one of the most common diseases among
older people and is a leading cause of disability. It affects the whole
joint structure including articular cartilage, synovial membrane,
subchondral bone, meniscus, and periarticular muscles1. The
structural changes of OA are due to a combination of risk factors,
ranging from common factors such as aging, obesity, being female,
smoking, genetics and joint injury, to mechanical and metabolic
factors1e4. Inﬂammation has been implicated in the pathogenesis of
OA. Synovitis is common in early5 and advanced6 OA, and it has
been associated with knee pain7 and progression of cartilageto: Changhai Ding, Menzies
a 7000, Australia. Tel: 61-3-
g).
s Research Society International. Pdegeneration8. The inﬂammatory changes in OA synovium include
synovial hypertrophy and hyperplasia with an increased number of
lining cells9, and an inﬁltration of the sublining tissue with a mixed
population of inﬂammatory cells including synovial macro-
phages10, activated B and T lymphocytes6. Local levels of pro-
inﬂammatory cytokines such as interleukin (IL)-1b, tumor necrosis
factor (TNF) a, and IL-6 produced by these cells are detectable even
in early OA but generally at lower levels than in rheumatoid
arthritis11e13, and in vitro and animal studies have documented that
these cytokines can enhance cartilage degradation or induce bone
resorption9,14,15.
Multiple studies have demonstrated that circulating levels of C-
reactive protein (CRP), a marker of low-grade systemic inﬂamma-
tion, are modestly elevated in OA and are associated with decreased
cartilage volume and disease progression16e18; however, the asso-
ciations between IL-6 and IL-1, the primary regulators of CRP, and
severity and progression of OA have been rarely reported. A recentublished by Elsevier Ltd. All rights reserved.
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signiﬁcantly associated with both IL-6 and CRP, and that incident
ROAwas signiﬁcantly predicted by IL-619. The same study found no
signiﬁcant associations between TNF-a and prevalent or incident
OA19, while a recent Dutch study suggested that ex vivo production
of TNF-a from whole blood samples upon lipopolysaccharide
stimulation was associated with radiological progression of knee
OA over 2 years20.
While OA disease progression is commonly measured by
radiographs, such means have been proven to have limited sensi-
tivity due to their two-dimensional nature and measurement error.
Magnetic resonance imaging (MRI) can visualize whole joint
structure directly and is recognised as a more sensitive, accurate
and reproducible tool than radiographic assessment to monitor OA
disease progression21. The aim of this study was to describe the
associations between circulating levels of inﬂammatory markers
(CRP, IL-1, TNF-a and IL-6), and both ROA prevalence and MRI-
detected knee cartilage loss over approximately 3 years in older
adults.
Materials and methods
Subjects
The study was carried out in southern Tasmania from March
until August 2002. The follow-up study was conducted approxi-
mately 3 years later (range 2.6e3.3 years). Subjects between ages
50 and 79 years were selected randomly from the roll of electors in
southern Tasmania (population 229,000) with an equal number of
men and women. Institutionalized persons were excluded. This
study was conducted as part of the Tasmanian Older Adult Cohort
Study, an ongoing, prospective, population-based study in 1100
subjects aimed at identifying the environmental, genetic, and
biochemical factors associated with the development and
progression of OA and osteoporosis (the overall response rate was
57% at baseline and 82% retention for follow-up). Subjects with
rheumatoid arthritis were excluded from analyses. The ﬁrst 172
subjects were selected to perform the measurements of serum
inﬂammatory markers at baseline and follow-up. At follow-up,
these measurements were not performed in nine subjects due to
insufﬁcient serum sample, leaving 163 subjects. The study was
approved by the Southern Tasmanian Health and Medical Human
Research Ethics Committee, and written informed consent was
obtained from all participants.
Anthropometrics and questionnaire
Height was measured to the nearest 0.1 cm (with shoes, socks,
and headgear removed) using a stadiometer. Weight was measured
to the nearest 0.1 kg (with shoes, socks, and bulky clothing
removed) using a single pair of electronic scales (Seca Delta Model
707, Bradford, MA) that were calibrated using a known weight at
the beginning of each clinic. Body mass index [BMI; weight (kg)/
height2 (m2)] was also calculated. Self-report of smoking status and
diseases including asthma, cardiovascular disease, and diabetes
were recorded by questionnaire. Steps per day were measured
using a pedometer worn on their dominant side for seven
consecutive days except during sleeping or water based activities.
Serum inﬂammatory markers measurement
Serum was isolated and refrigerated overnight in plastic tubes,
at which time aliquots were prepared and stored at80C. The IL-1
b, IL-6 and TNF-awere measured at baseline and then at follow-up
with a solid-phase, two-site chemiluminescent enzymeimmunometric assaymethod by use of IMMULITE IL-1 b, IMMULITE
IL-6 and IMMULITE TNF-a (all from EURO/DPC Llanberis, Gwynedd,
United Kingdom). Samples with undetectable cytokine concentra-
tions were assigned a value corresponding to the lower limit of
detection of the assay (1.5 pg/ml for IL-1 b, 2 pg/mL for IL-6 and
1.7 pg/mL for TNF-a). The coefﬁcients of variation (CVs) in our
hands were 3% for IL-1 b, 8% for IL-6 and 6% for TNF-a22.
Testing high-sensitivity CRP (hs-CRP) was performed by using
the CRP-Latex (II) immunoturbidimetric assay (Abbott Diagnostic’s
c8000 Architect). The lower detection limit of the assay is 0.01 mg/L.
The CV in our hands was of the order of 4.8%22.
Changes in these markers were calculated as: change per
annum¼ (follow-up value baseline value)/(time between two
visits in years).
Knee X-ray and knee pain assessment
A standing anteroposterior semiﬂexed view of the right and left
kneeswith 15 of ﬁxed knee ﬂexionwas performed in all subjects at
baseline and scored individually for osteophytes and joint space
narrowing (JSN) on a scale of 0e3 (0¼ normal and 3¼ severe)
according to the Osteoarthritis Research Society International
(OARSI) atlas as previously described23. The presence of medial or
lateral tibiofemoral JSN or osteophytes was deﬁned as any score of
1 in that compartment. The presence of JSN or osteophytes in the
whole tibiofemoral compartment was deﬁned as the presence of
that feature in either of the medial or lateral compartments.
Knee pain (on ﬂat surface, going up/down stairs, at night,
sitting/lying and standing upright) was assessed by self-adminis-
tered questionnaire using the Western Ontario McMaster Osteo-
arthritis Index (WOMAC) with a 10-point scale from 0 (no pain,
stiffness or no function problems) to 9 (most severe pain, stiffness
or severe function problems)24. Each component of joint pain was
summed to create a total pain (0e45) score. Prevalent knee pain
was deﬁned as a total score of 1.
Knee cartilage volume and tibial bone area measurements
MRI scans of the right knee were performed at baseline and
follow-up. Knees were imaged in the sagittal plane on a 1.5-T whole
body magnetic resonance unit (Picker, Cleveland, OH) and a fat-
saturated T1-weighted spoiled gradient echo sequence was used.
Knee cartilage volume was determined by means of image pro-
cessing on an independent workstation as previously described2,25.
The volumes of individual cartilage plates (medial tibial, and lateral
tibial) were isolated from the total volume by manually drawing
disarticulation contours around the cartilage boundaries on
a section-by-section basis. These data were then resampled by
means of bilinear and cubic interpolation (area of 312 and 312 mm
and 1.5 mm thickness, continuous sections) for the ﬁnal 3-D
rendering. The CVs for cartilage volume measures in our hands
were 2.1e2.6%25. Rates of change in cartilage volume were calcu-
lated as: percentage change per annum¼ [100 [(follow-up vol-
ume baseline volume)/baseline volume]/(time between two
scans in years)].
Tibial bone area at the medial and lateral compartments was
determined as previously described23.
Data analysis
T-tests or c2-tests (where appropriate) were used to compare
means or proportions. Quartiles of IL-6 or TNF-a were used in
analysis, because nearly a quarter of subjects had IL-6 levels under
the lower limits of detection. The associations between quartiles of
IL-6/TNF-a and presence of knee ROA (JSN or osteophytes), both
Table I
Characteristics of participants
IL-6<median
(n¼ 85)
IL-6median
(n¼ 87)
P-values
Age (year) 61.4 (6.3) 63.8 (7.8) 0.029*
Female sex (%) 48 45 0.656**
BMI (kg/m2) 27.1 (3.5) 27.8 (4.8) 0.269*
Knee pain (%) 45 46 0.868**
Knee pain severity (0e45) 3.1 (5.3) 3.0 (5.2) 0.921*
Ever smoking (%) 53 48 0.494**
Steps per day (1000) 11.1 (2.7) 8.8 (3.7) <0.001*
Asthma (%) 17 13 0.434**
Cardiovascular diseases (%) 4 5 0.678**
Diabetes (%) 5 6 0.706**
Right knee JSN (%) 47 65 0.017**
Left knee JSN (%) 51 73 0.003**
Right tibiofemoral
osteophytes (%)
5 12 0.233**
Left tibiofemoral
osteophytes (%)
4 14 0.025**
Medial tibial cartilage
volume (ml)
2.4 (0.6) 2.3 (0.6) 0.438*
Lateral tibial cartilage
volume (ml)
2.9 (0.7) 2.8 (0.7) 0.631*
Medial tibial bone area
(mm2)
21.2 (3.2) 21.0 (3.0) 0.661*
Lateral tibial bone area
(mm2)
12.1 (1.9) 12.4 (2.3) 0.808*
Hs-CRP (mg/l) 1.6 (1.0, 3.7) 2.6 (1.4, 5.4) 0.009**
TNF-a (pg/ml) 6.1 (4.4, 8.6) 9.3 (6.5, 13.2) <0.001**
Mean standard deﬁnition (SD) or median (interquartile range) except for percent-
ages. IL-6 median: 2.9 pg/ml. * Unpaired t-test except ** c2-tests.
Table II
Associations between knee ROA at the right and left knees and cytokines: cross-
sectional data
Univariable OR (95% CI) Multivariable* OR (95% CI)
IL-6 (per quartile)
Medial JSN 1.37 (1.04, 1.80) 1.42 (1.07, 1.87)
Lateral JSN 1.25 (0.90, 1.73) 1.23 (0.88, 1.71)
Medial OP 1.08 (0.63, 1.87) 0.81 (0.49, 1.32)
Lateral OP 1.62 (0.71, 3.67) 1.47 (0.66, 3.25)
TNF-a (per quartile)
Medial JSN 1.50 (1.13, 1.98) 1.47 (1.11, 1.95)
Lateral JSN 1.07 (0.76, 1.51) 1.07 (0.77, 1.49)
Medial OP 1.03 (0.60, 1.76) 0.78 (0.47, 1.30)
Lateral OP 1.12 (0.52, 2.42) 1.16 (0.55, 2.48)
OP: osteophytes. Dependent variable: presence of JSN or osteophytes; Independent
variable: quartiles of IL-6 (2.0, >2.0e2.9, >2.9e4.0, 4.0 pg/ml) or TNF-a (5.1,
>5.1e7.3, >7.3e11.6, 11.6 pg/ml). Bold denotes statistically signiﬁcant result.
* Adjusted for sex, age, BMI, smoking, steps per day, knee pain, knee JSN if
osteophytes, osteophytes if JSN, asthma, cardiovascular diseases, and diabetes.
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including sex, age, BMI, smoking, steps per day, knee JSN if osteo-
phytes, osteophytes if JSN, asthma, cardiovascular diseases, and
diabetes, were analysed by logistic regression using generalized
estimating equations (GEE’s) to account for the correlation of data
between both knees. An exchangeable correlation matrix was used
as observations are clustered (and not time dependent) and all
models used robust variance estimates to ensure valid standard
errors, irrespective of correlation structure or whether the residuals
are not identically distributed across subjects. Univariable and
multivariable linear regression analyses were used to examine the
associations between quartiles of IL-6/TNF-a or change in quartiles
and cartilage volume or change in cartilage volume before and after
adjustment for potential confounding factors. Further adjustment
for each biomarker (TNF-a for IL-6 or IL-6 for TNF-a) was made to
test the independence of these two predictors from each other.
Analyses were also conducted using the lowest quartile (quartile 1)
as a reference, to compare the individual effect of quartile 2, 3 or 4
categorically in predicting outcome measures. Standard diagnostic
checks of model ﬁt and residuals were routinely made and points
with high inﬂuence were investigated. The linearity for the asso-
ciations between quartiles of IL-6 or TNF-a and outcome measures
was determined.
Interactions between IL-6/TNF-a and other variables (such as
sex) on ROA or change in cartilage volume were investigated. A P-
value less than 0.05 (two-tailed) or a 95% conﬁdence interval not
including the null point was regarded as statistically signiﬁcant. All
statistical analyses were performed on SPSS version 12.0 for
Windows (Chicago, IL), or Stata statistical software, release 10.0
[College Station (TX): Stata Corporation, 2006].
Results
A total of 172 subjects (47% female) aged between 52 and 78
(mean 63 years) participated and 163 had complete data at follow-
up. Knee pain was prevalent in 45% of subjects. There were no
signiﬁcant differences in demographic factors, ROA and cartilage
loss between the current cohort and the subjects who did not have
serum markers measured (data not shown). The serum levels of
inﬂammatory markers were generally low with 98.4% of IL-1
b undetectable in this sample, so this was not further analysed. The
median level of IL-6 was 2.9 pg/mL, TNF-a was 7.3 pg/mL and hs-
CRP was 2.2 mg/L. The numbers of IL-6 and TNF-a measurements
below their respective lower limits of detection were 51 (w26%)
and 25 (w13%) at baseline; and 32 (w19%) and 17 (w10%) at follow-
up. Characteristics of the subjects are presented in Table I. There
were no signiﬁcant differences between subjects with high
(median) and low (<median) levels of IL-6 in terms of sex, BMI,
smoking, disease status, tibial cartilage volume, and tibial bone
area; however, subjects with high levels of IL-6 (median) were
older, had less steps per day and higher levels of TNF-a and hs-CRP,
and greater prevalence of JSN and left tibiofemoral osteophytes
(Table I). The interactions between sex and IL-6 or TNF-a on JSN or
loss of cartilage volume were all non signiﬁcant (data not shown),
so men and women were combined for analyses.
At baseline, quartiles of IL-6 were associated with prevalent JSN
(grade 1) in the medial tibiofemoral compartments but not with
JSN in lateral tibiofemoral compartment (Table II). After adjustment
for sex, age, BMI, smoking, steps per day and other potential
confounders, IL-6 was associated with 1.4-fold increased odds per
quartile of medial tibiofemoral JSN (P¼ 0.015, Table II). The asso-
ciation became non-signiﬁcant after further adjustment for TNF-
a (P¼ 0.099, data not shown). IL-6 was also associated with 1.3-fold
increased odds per quartile of whole tibiofemoral (prevalence in
either medial or lateral compartment) JSN (P¼ 0.016). Quartiles ofIL-6 were not signiﬁcantly associated with osteophytes (Table II);
however, high levels of IL-6 (median) were associated with
greater prevalence of osteophytes in whole tibiofemoral compart-
ment of left knee compared with low levels of IL-6, before (Table I)
and after adjustment for potential confounders including TNF-
a (OR¼ 7.4, P¼ 0.021). When each quartile was examined as an
independent predictor for prevalent JSN, quartiles 3 and 4 of IL-6
were associated with greater prevalence of JSN, but were not
signiﬁcant, despite an overall signiﬁcant positive trend for medial
JSN (Table III).
Similarly to IL-6, quartiles of TNF-a were associated with JSN in
the medial tibiofemoral compartments but not with JSN in lateral
tibiofemoral compartment (Table II). After adjustment for potential
confounders, TNF-a was associated with 1.5-fold increased odds
per quartile of medial tibiofemoral JSN (P¼ 0.007) (Table II). This
Table III
Associations between knee radiographic JSN at the right and left knees and cytokines: comparisons between quartiles of cytokines in cross-sectional data
Model Predictor Compartment OR (95% CI) P-value for trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Univariable IL-6 Medial 1.00 (Reference) 0.46 (0.20, 1.10) 1.81 (0.73, 4.47) 1.84 (0.77, 4.38) 0.027
Lateral 1.00 (Reference) 1.06 (0.36, 3.08) 2.20 (0.80, 6.07) 1.66 (0.56, 4.90) 0.178
TNF-a Medial 1.00 (Reference) 1.31 (0.56, 3.07) 1.44 (0.61, 3.39) 3.90 (1.56, 9.77) 0.004
Lateral 1.00 (Reference) 0.64 (0.22, 1.84) 0.80 (0.29, 2.26) 1.16 (0.43, 3.08) 0.687
Multivariable* IL-6 Medial 1.00 (Reference) 0.43 (0.16, 1.12) 1.75 (0.69, 4.39) 1.87 (0.70, 5.02) 0.030
Lateral 1.00 (Reference) 1.13 (0.34, 3.74) 2.28 (0.75, 6.88) 1.55 (0.43, 5.54) 0.320
TNF-a Medial 1.00 (Reference) 0.87 (0.34, 2.27) 1.21 (0.46, 3.22) 3.21 (1.19, 8.65) 0.016
Lateral 1.00 (Reference) 0.42 (0.13, 1.36) 0.58 (0.17, 1.96) 0.75 (0.24, 2.31) 0.874
Dependent variable: presence of JSN; Independent variable: quartiles 2, 3 or 4 of IL-6 (>2.0e2.9, >2.9e4.0, 4.0 pg/ml) or TNF-a (>5.1e7.3, >7.3e11.6, 11.6 pg/ml) vs
quartile 1. Bold denotes statistically signiﬁcant result.
* Adjusted for sex, age, BMI, smoking, steps per day, knee pain, osteophytes, asthma, cardiovascular diseases, and diabetes.
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6 (P¼ 0.035, data not shown). TNF-a was also associated with 1.4-
fold increased odds per quartile of whole tibiofemoral (prevalence
in either medial or lateral compartment) JSN (P¼ 0.007). In addi-
tion, in adjusted analysis, subjects in the highest quartile of TNF-
a were 3.2 times more likely to have prevalent medial JSN than
those in the lowest quartile (Table III). TNF-a analysed by either
quartiles (Table II) or median cutpoint was not associated with
osteophytes.
At baseline, IL-6 was not associated with tibial cartilage volume
(Table I). However, over approximately 3 years, subjects in the
highest quartile of IL-6 had greater loss of both medial and lateral
tibial cartilage volume than those with lowest quartile of IL-6, in
unadjusted analyses (both P< 0.05, data not shown). Quartiles of
IL-6 were associated with loss of both medial and lateral tibial
cartilage volume after adjustment for covariates (Table IV, P< 0.05
for medial and P< 0.01 for lateral) and these remained largelyTable IV
Associations between cytokines at baseline, change in cytokines and change in knee
cartilage volume: longitudinal data
Multivariable*
b (95% CI)
Multivariable**
b (95% CI)
Baseline IL-6 (quartiles)
Medial tibial
(%/year per quartile)
L1.07 (L1.98,L0.17) L1.19 (L2.21,L0.18)
Lateral tibial
(%/year per quartile)
L0.80 (L1.58,L0.03) L1.35 (L2.23,L0.46)
IL-6 change in quartile
Medial tibial
(%/year per quartile)
L1.08 (L1.90,L0.25) L1.18 (L2.10,L0.25)
Lateral tibial
(%/year per quartile)
0.55 (1.26, 0.16) L1.06 (L1.86,L0.25)
Baseline TNF-a (quartiles)
Medial tibial
(%/year per quartile)
0.59 (1.47, 0.30) 0.60 (1.61, 0.41)
Lateral tibial
(%/year per quartile)
0.19 (0.97, 0.58) 0.29 (1.20, 0.63)
TNF-a change in quartile
Medial tibial
(%/year per quartile)
L1.24 (L2.00,L0.45) L1.27 (L2.20,L0.33)
Lateral tibial
(%/year per quartile)
0.37 (1.03, 0.30) 0.51 (1.36, 0.33)
b: regression coefﬁcient. Dependent variable: change in cartilage volume, %/year.
Independent variable: quartiles of IL-6 (2.0, >2.0e2.9, >2.9e4.0, 4.0 pg/ml) or
TNF-a (5.1, >5.1e7.3, >7.3e11.6, 11.6 pg/ml). Bold denotes statistically signiﬁ-
cant result.
* Adjusted for baseline IL-6 or TNF-a (for change in IL-6 or TNF-a, respectively) or
change in IL-6 or TNF-a (for baseline IL-6 or TNF-a, respectively).
** Further adjusted for sex, age, BMI, smoking, steps per day, tibial bone area, knee
pain, asthma, cardiovascular diseases, and diabetes.unchanged further adjustment for TNF-a (P< 0.05 for medial and
P< 0.01 for lateral, data not shown). Change in quartiles of IL-6 was
also signiﬁcantly associated with loss of both medial and lateral
tibial cartilage volume after adjustment for potential confounders
(Table IV; both P< 0.05). These associations decreased in magni-
tude and only remained signiﬁcant for lateral cartilage volume loss
(P< 0.05, data not shown) after adjustment for change in TNF-a.
When quartiles were examined separately in adjusted analyses, we
found that the highest quartile of baseline IL-6 had 3.5% and 4.2%
per year more loss of medial and lateral tibial cartilage volume,
respectively, when compared to the lowest quartile (Table V). Also,
quartile 3 of baseline IL-6 had 2.7% per year more loss of lateral
tibial cartilage volume than quartile 1 (Table V).
Baseline TNF-a was not associated with baseline tibial cartilage
volume (data not shown) and change in tibial cartilage volume
(Table IV); however, change in quartiles of TNF-a was associated
with loss of medial tibial cartilage volume both before and after
adjustment for potential confounders (Table IV, both P< 0.05). This
association decreased in magnitude but remained signiﬁcant after
further adjustment for change in IL-6 (data not shown). No quartile
of TNF-a contributed signiﬁcantly more to cartilage volume loss
than the lowest quartile (Table V).
We did not ﬁnd any signiﬁcant association between hs-CRP and
JSN, cartilage volume and change in cartilage volume (data not
shown), or signiﬁcant results using IL-6 or TNF-a as a continuous
predictor.
Discussion
This study is the ﬁrst, to our knowledge, to determine the
associations between circulating inﬂammatory markers and carti-
lage loss in a population-based study of older adults. Cross-
sectionally, serum levels of IL-6 and TNF-a were both associated
with JSN in the medial tibiofemoral compartment (both P< 0.05)
but not with tibial cartilage volume. Longitudinally, serum levels of
IL-6 predicted loss of medial and lateral tibial cartilage volume, and
change in IL-6 and TNF-a were associated with loss of medial and
lateral tibial cartilage volume. The associations of IL-6 and TNF-
awere, in part, dependent of each other, except for the associations
between baseline IL-6 and cartilage loss. In contrast, serum levels of
hs-CRP were not associated with JSN, tibial cartilage volume and
change in tibial cartilage volume.
IL-6 is produced by T cells, B cells, monocytes, ﬁbroblasts26, as
well as osteoblasts from subchondral bone, osteophytes of OA
under mechanical loading and adipocytes of the infrapatellar fat
pad27e29. IL-6 can stimulate synoviocyte proliferation and osteo-
clast activation, leading to synovial pannus formation and matrix
metalloproteinases production, which induces joint and cartilage
destruction26. IL-6 has been reported to correlate with clinical
Table V
Associations between cytokines at baseline and change in knee cartilage volume: comparisons between quartiles of cytokines in longitudinal data
Model Predictor Compartment b (95% CI) P-value for trend
Quartile 1 Quartile 2 Quartile 3 Quartile 4
Multivariable* IL-6 Medial 0.00 (Reference) 1.64 (4.33, 1.04) 2.52 (5.82, 0.78) 2.58 (5.62, 0.45) 0.020
Lateral 0.00 (Reference) 2.27 (4.60, 0.07) 2.04 (4.93, 0.84) L2.82 (L5.31, L0.32) 0.043
TNF-a Medial 0.00 (Reference) 0.67 (1.53, 2.86) 0.05 (3.09, 2.99) 2.17 (5.21, 0.86) 0.192
Lateral 0.00 (Reference) 0.32 (1.82, 2.47) 1.20 (3.82, 1.42) 0.37 (2.98, 2.25) 0.622
Multivariable** IL-6 Medial 0.00 (Reference) 1.07 (3.49, 1.34) 2.56 (5.38, 0.26) L3.50 (L6.62, L0.37) 0.022
Lateral 0.00 (Reference) 2.10 (4.20, 0.00) L2.65 (L5.10, L0.19) L4.21 (L6.93, L1.50) 0.003
TNF-a Medial 0.00 (Reference) 0.46 (2.05, 2.97) 0.14 (3.00, 2.72) 1.73 (4.85, 1.40) 0.241
Lateral 0.00 (Reference) 0.07 (2.34, 2.20) 0.62 (3.22, 1.98) 0.78 (3.62, 2.07) 0.539
Dependent variable: change in cartilage volume, %/year; Independent variable: quartiles 2, 3 or 4 of IL-6 (>2.0e2.9, >2.9e4.0, 4.0 pg/ml) or TNF-a (>5.1e7.3, >7.3e11.6,
11.6 pg/ml) vs quartile 1. Bold denotes statistically signiﬁcant result.
* Adjusted for baseline IL-6 or TNF-a (for change in IL-6 or TNF-a, respectively) or change in IL-6 or TNF-a (for baseline IL-6 or TNF-a, respectively).
** Further adjusted for sex, age, BMI, smoking, steps per day, tibial bone area, knee pain, asthma, cardiovascular diseases, and diabetes.
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therapies involving blockade of IL-6 functions have constituted
a new therapeutic strategy for rheumatoid arthritis and other
inﬂammatory diseases30. In contrast, the role of IL-6 in OA remains
much less studied.
In the Hartley guinea pig model of OA, serum levels of IL-6 were
found to correlate positively with total histological score of OA
(assessing cartilage structure abnormalities and proteoglycan loss),
independently of age and weight14. The ﬁndings from clinical
studies are far less convincing. In 41 patients with knee OA, IL-6
expression in synovial membrane was not associated with Kell-
greneLawrence radiological score and WOMAC pain31, and in 29
patients with knee or hip OA, IL-6 in serum and urine was not
associated with clinical measures such as soft tissue swelling32.
These two studies are both limited by small sample size. Penninx
et al.33 reported that the serum concentration of IL-6 was not
associated with WOMAC pain, stiffness and function and ROA, but
tended to be associated with slower walking speed in 272 patients
with knee OA. Toncheva et al.34 reported that serum levels of IL-6
were signiﬁcantly elevated in patients with active OA (expressing
swelling, local hyperthermia and high erythrocyte sedimentation
rate) but not in those with inactive OA (lacking above symptoms),
compared with healthy controls; however, the associationwith JSN
or cartilage loss was not reported. Livshits et al. reported that
circulating IL-6 predicted the incidence of whole-joint knee ROA
assessed by the KellgreneLawrence scoring system in a population
of women19. Furthermore, Sakao et al.35 reported that IL-6
expression was signiﬁcantly enhanced in subchondral bone oste-
oblasts with knee OA compared to subchondral bone osteoblasts
without knee OA, and IL-6 expression was greater in patient with
severe cartilage damage than those with mild cartilage damage.
In this study, we found that serum levels of IL-6 were associated
with JSN in the medial tibiofemoral compartment and whole
compartment. Importantly, baseline IL-6 levels were associated
with loss of tibial cartilage volume, independently of TNF-a, and
change in IL-6 was also associated with change in tibial cartilage
volume over approximately 3 years. These associations were
independent of potential confounders including age, sex, BMI, tibial
bone area, smoking, physical activity and other disease status.
These results suggest that IL-6 may play a role in cartilage loss at an
early stage of knee OA. This may have clinical signiﬁcance; for
example, if rates of loss are constant over time it can be estimated
that patients with low level IL-6 (<2 pg/ml, 0.6% per annum loss in
this sample) will never lose the amount of medial tibial cartilage
required to reach end-stage OA36 (when 60% of cartilage is lost) as it
will take 100 years, but this deteriorationwill take only 15 years for
patients with high IL-6 levels (>4.0 pg/ml, 4.1% per annum loss).
This effect would be of major clinical importance. Furthermore, wefound that prevalence of osteophytes was greater in subjects with
high levels of serum IL-6 (median) than those with low levels of
IL-6. This is in linewith a recent report which demonstrated that IL-
6 production in osteoblasts isolated from the OA osteophytes was
signiﬁcantly higher than that of osteoblasts from subchondral bone
without OA27, and suggest that IL-6 may play a role in osteophyte
formation in OA, though this needs to be conﬁrmed by longitudinal
studies.
TNF-a appears to play a pivotal role in cartilage matrix degra-
dation and bone resorption in OA. It can induce the production of
other cytokines (such as IL-6), matrix metalloproteinases and
prostaglandins9, and inhibit the synthesis of proteoglycans and
type II collagen6. TNF-a mRNA levels were up-regulated in OA-
affected cartilage compared to normal cartilage37. Penninx et al.33
reported that in patients with knee OA, serum levels of TNF-
a were not associated with WOMAC knee pain, stiffness and
radiographic scores, but higher serum levels of the soluble recep-
tors TNF-sR1 and TNF-sR2 were signiﬁcantly associated with
greater knee pain and stiffness, and tended to be associated with
worse radiographic scores. A Dutch group reported that high innate
ex vivo production of TNF-a in whole-blood assay upon lipopoly-
saccharide stimulationwas not associated with an increased risk of
OA38; however, longitudinally, patients in the highest quartile of
TNF-a production had a 6-fold increased risk of JSN progression
compared to those in the lowest quartile over 2 years20.
In this study, we found that serum levels of TNF-a were signif-
icantly associated with JSN in tibiofemoral compartments. Our
results associating TNF-a with prevalent JSN do not match the
negative ﬁndings of Livshits et al.19, perhaps due to their different
measure of ROA. Although serum levels of TNF-a at baseline were
not associated with loss of cartilage volume, change in TNF-a levels
was associated with change in cartilage volume over approximately
3 years. These results suggest that TNF-a plays a role in cartilage
loss of early OA but the causal relationship needs to be explored in
future studies.
It was expected that the signiﬁcant associations detected in this
studymight decrease inmagnitude or even because non-signiﬁcant
after adjustment for TNF-a for IL-6 or IL-6 for TNF-a, because serum
levels of IL-6 and TNF-awere related to each other. This was true for
most analyses. The associations between baseline IL-6 and longi-
tudinal cartilage volume loss remained largely unchanged after
adjusting for TNF-a, and the association between baseline TNF-
a and medial JSN remained signiﬁcant after adjusting for IL-6. In
contrast, there are no signiﬁcant associations between TNF-a and
longitudinal cartilage volume loss, and the association between
baseline IL-6 andmedial JSN became non-signiﬁcant after adjusting
for TNF-a. The reasons for these inconsistencies are unclear, but it
may suggest that IL-6 plays a more important role in cartilage loss
O. Stannus et al. / Osteoarthritis and Cartilage 18 (2010) 1441e14471446at an earlier stage and TNF-a plays a more important role at a later
stage when JSN is seen on X-ray. These preliminary ﬁndings need to
be replicated by further studies with larger sample size and longer
study period.
We did not ﬁnd any cross-sectional associations between tibial
cartilage volume and either IL-6 or TNF-a in this study, despite
ﬁnding associations between change in those variables and change
in cartilage volume. The reasons for this are unclear, butmay be due
to the fact that knee cartilage volume measured at a given point in
time cannot distinguish normal from swollen cartilage39. Although
IL-1 has been demonstrated to play a major role in cartilage
destruction of OA by in vitro and animal studies9, serum levels of IL-
1 were mostly undetectable in this study, suggesting IL-1 may be
not as important as IL-6 and TNF-a in initiating cartilage loss of
early OA in the general population. We also did not ﬁnd any asso-
ciation between serum levels of hs-CRP, JSN and cartilage loss in
older adults, even though serum hs-CRP levels signiﬁcantly corre-
lated with serum IL-6 levels. This differs from previous reports in
established OA16,17, though studies of CRP in incident knee OA are
equivocal19,40, suggesting CRP may not be the best marker of
inﬂammation in early OA.
The strengths of the present study lie in the measurements of
inﬂammatory markers on two occasions which allowed us to
assess the variation in these markers over time. Variation in
inﬂammatory markers may be less affected by natural antagonists
in the serum than cross-sectional levels of these markers. Our
study has several potential limitations. First, the response rate at
baseline was 57%, possibly due to the demands on study partici-
pants in that each visit took 3 h. This did leave the possibility open
for selection bias. However, there were no signiﬁcant differences
in age and gender between those responded and those did not. We
also had high rates of retention (82%) to offset this. Second, our
modest sample size may not allow us to examine weak associa-
tions between some inﬂammatory markers (such as hs-CRP) and
osteoarthritic changes. A third limitation is our measurement of
inﬂammatory marker levels in serum rather than levels in syno-
vial ﬂuid, which may represent a more appropriate and sensitive
measure for inﬂammatory markers in knee OA (such as IL-6 and
TNF-a). Also, as we did not ﬁnd signiﬁcant results using predictors
as continuous variables, we cannot rule out the possibility that the
relationships are model-speciﬁc, and replications using an assay
with higher sensitivity which may provide signiﬁcant results with
continuous IL-6 or TNF-a data are required in future studies.
Lastly, measurement error may result in some non-differential
misclassiﬁcation; however, as all measures (e.g., cartilage volume,
JSN, and inﬂammatory markers) were highly reproducible, this is
likely to be low.
In conclusion, circulating levels of IL-6 in older people are
associated with knee JSN and knee cartilage loss, and level of TNF-
a is associated with JSN, suggesting low level inﬂammation may
play a role in the pathogenesis of knee OA.Contributions
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